Pennsylvania Medicaid coverage for Zepbound (Osa)

What you need to qualify

• BMI of 35 or higher
• Prior trial of 3 other GLP-1 medications (Ozempic, Wegovy, and Mounjaro)
• Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Recent BMI documentation (>= 35 kg/m2)
• Documentation of moderate-to-severe OSA diagnosis within last 2 years: per AASM/consensus guidelines OR AHI >= 15 events/hour on sleep study
• Documentation of at least one OSA clinical symptom: ESS score >= 10 (excessive daytime sleepiness) OR sleep-related quality of life impairment (snoring, nocturnal choking, insomnia, partner disruption, morning headaches, nocturia)
• PAP adherence documentation: >= 4 hours/night on 70% of nights in a consecutive 30-day period — OR documentation of PAP intolerance with troubleshooting attempts AND utilization of or intolerance to an oral appliance
• Documentation of 6-month prior trial of lifestyle changes and behavioral modifications OR medical reason for immediate treatment
• Documentation of therapeutic failure of Ozempic (semaglutide) at max FDA-approved dose, AND Wegovy (semaglutide) at max FDA-approved dose, AND Mounjaro (tirzepatide) at max FDA-approved dose — OR contraindication/intolerance to each (with troubleshooting documentation over >= 1 month if intolerance-based)
• Documentation of age-appropriateness per FDA labeling, compendia, or peer-reviewed literature
• Documentation of no contraindication to Zepbound
• If therapeutic duplication: documentation of intent to transition or medical reason for concomitant use

Approval and renewal

• Initial approval: 6 months
• Renewal: every 6 months
• To renew, the plan looks for at least 5% weight loss from the starting weight and Renewal (OSA): (1) If on GLP-1 <6 months: documentation of lifestyle changes and behavioral modifications; (2) If on GLP-1 >=6 months AND titration complete AND >=3 consecutive months at max tolerated dose: must show 5% total body weight loss and documentation of dietary changes; (3) If on GLP-1 >=6 months but titration not complete or <3 consecutive months at max tolerated dose: may approve up to 3-month trial extension at max tolerated dose with documentation of dietary changes; (4) PAP adherence or PAP intolerance with oral appliance trial maintained; (5) If on GLP-1 >=1 year: must document improvement in OSA symptoms (e.g., decrease in AHI from baseline, improvement in daytime sleepiness); (6) Step-therapy: therapeutic failure/contraindication/intolerance to max doses of Ozempic, Wegovy, AND Mounjaro. BMI and AHI baseline not re-confirmed at renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

• Mild OSA excluded (moderate-to-severe only, AHI >= 15)
• Overweight/obesity treatment indication excluded
• Saxenda (liraglutide) not covered for any indication

Policy note: Zepbound is non-preferred for OSA. Requires step-through therapeutic failure/contraindication/intolerance to maximum FDA-approved doses of ALL THREE of: Ozempic, Wegovy, AND Mounjaro before Zepbound. OSA diagnosis must be confirmed within last 2 years. PAP adherence is defined as >= 4 hours/night on 70% of nights in a consecutive 30-day period. PAP intolerance pathway requires documentation of troubleshooting strategies (mask issues, humidity, claustrophobia) and then either use of or intolerance to an oral appliance. Renewal at >=6 months requires 5% total body weight loss (if titration complete and >=3 months at max tolerated dose) with dietary change documentation; if not yet at max dose, up to 3-month extension may be approved. At >=1 year, must document OSA symptom improvement (AHI reduction or daytime sleepiness improvement). Approval up to 6 months per cycle unless reviewer specifies otherwise. Prescriptions limited to 1-month supply per fill.

Policy effective January 1, 2026 · verified June 4, 2026 · source: mab2025112403.pdf